A patient with gout and renal impairment (eGFR 28 mL/min) is on febuxostat. After a gout flare, colchicine is added. Which pharmacokinetic concern is most relevant for colchicine dosing in this scenario?
- A Colchicine is hepatically cleared via CYP2D6 and renal impairment has no effect on its pharmacokinetics
- B Febuxostat competitively inhibits CYP3A4, doubling colchicine plasma levels in combination
- C Colchicine is primarily renally eliminated and a substrate of P-glycoprotein and CYP3A4; impaired renal clearance requires dose reduction to prevent toxicity including myopathy and neuropathy ✓
- D Colchicine is converted to active metabolite 3-O-demethylcolchicine by CYP3A4; renal impairment reduces metabolite clearance, increasing efficacy
Explanation
Colchicine has a narrow therapeutic index and its pharmacokinetics are significantly altered by renal impairment. Approximately 10–20% of a colchicine dose is eliminated unchanged by the kidneys, and its principal active metabolites are also renally cleared. Colchicine is also a substrate of P-glycoprotein (P-gp/ABCB1) and CYP3A4; in renal impairment, P-gp expression in intestinal and renal tubular cells may be reduced, increasing bioavailability. Current guidelines recommend using colchicine with caution when eGFR is 15–30 mL/min and avoidance below 15 mL/min. Additionally, concomitant use of P-gp inhibitors or strong CYP3A4 inhibitors can precipitate life-threatening colchicine toxicity (myopathy, neuropathy, bone marrow suppression, multiorgan failure) even at standard doses.
Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.